Details checkedClinical trial listing onlyCheckedregistry

Sun Yat-sen autologous monocyte vesicles sudden deafness study

Also known as: Autologous Blood Monocyte Vesicles for the Treatment of Sudden Deafness, autologous blood monocyte vesicles, apoVs, NCT06707389, SYSKY-2023-1250-02

Institution-led study

Primary source

Sponsor / Institution

Institution-led study

Program Type

Therapeutic

Modality

Cell Therapy

Stage

Phase 1

Status

Active

Target Gene

—

Route / Mode

Intratympanic injection

Confidence

80%

Status Confidence

Status needs checking

Evidence Strength

Needs more support

Last Reviewed

2026-06-09

Geography

China

Population

adult, sudden, sensorineural, autologous, extracellular-vesicles, cell-derived-vesicles

Trial IDs

Mechanism

Intratympanic autologous blood monocyte extracellular vesicles compared with intratympanic methylprednisolone for severe sudden deafness/sudden sensorineural hearing loss.

Indications

Hearing Loss Sudden Hearing Loss Sensorineural Hearing Loss Tinnitus

Notes

Verified as a Sun Yat-sen Memorial Hospital early Phase 1 institution-led study of autologous monocyte vesicles for sudden deafness. The registry lists it as not yet recruiting, so it should be treated as an early study-level record, not a commercial cell-therapy program.

Evidence & Sources

1 structured sources

clinicaltrials

Supports: canonicalName, aliases, allCompanies, isIndustrySponsored, stage, status, route, indications...

IDs: NCT06707389, SYSKY-2023-1250-02

Open

Key Events

2024-11-27

Autologous monocyte vesicles sudden deafness study first posted

2024-12-27

ClinicalTrials.gov update lists the study as not yet recruiting

Clinical Trials (1)